利用证据蓝图倡议转变阿斯特拉泽内卡西班牙的能力发展
Jesús Medina1, Joaquín Sánchez-Covisa1, Javier Nuevo1
1Biopharmaceuticals Medical, AstraZeneca Farmacéutica Spain, Medical Affairs Department, C. del Puerto de Somport 21-23, Fuencarral-El Pardo, 28050, Madrid, Spain.
医疗事务 (MA) 现在整合了真实世界的数据 (RWD). 西班牙AstraZeneca使用证据蓝图来评估和增强RWD能力,重点关注价值战略和以患者为中心的医疗保健创新证据.
科学领域:
- 制药行业 制药行业 制药行业
- 卫生经济学和结果研究研究.
- 现实世界的证据生成.
背景情况:
- 医疗事务 (MA) 的作用已经从传统的证据传播演变为整合现实世界数据 (RWD) 和各种数据源.
- 西班牙AstraZeneca (AZ) 发现需要评估和改进其证据生成能力,以与全球和当地优先事项保持一致.
研究的目的:
- 系统地评估AZ西班牙目前的证据生成能力,使用证据蓝图框架.
- 确定具体的差距,并制定有针对性的战略,以加强证据的产生.
主要方法:
- 在使用"证据蓝图"的十个核心领域进行了系统的自我评估.
- 采用了四个阶段的方法:定义能力,评估成熟度,制定路线图和实施变化.
主要成果:
- 确定了需要改进的五个优先领域,包括创新价值策略/付款人证据和RWD愿景和战略.
- 关键行动包括制定基于结果的协议的流程,为RWD绘制数据库,创建跨职能证据规划,建立研究伙伴关系和采用以患者为中心的方法.
结论:
- 证据蓝图框架有效地发现了缺口,并指导了AZ西班牙证据生成能力的改进.
- 与AZ的MA 2030愿景相一致的倡议推动创新,增强决策,并为医疗保健生态系统做出贡献.
更多相关视频
11:29Measuring the Functional Abilities of Children Aged 3-6 Years Old with Observational Methods and Computer Tools
Published on: June 20, 2020
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
相关概念视频
SBAR II: Application of SBAR
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
Preclinical Development: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Discovery: Overview
